Alamar Biosciences, Inc.
ALMR
Get informed when a big investor buys or sells
+ FollowMarket Cap$266.81M
Close$
$-25.78
178.3% downside
Current Fair Value
178.3% downsideOvervalued by 178.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $266.81 Million |
|---|---|
| Enterprise Value | $544.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.45 |
| Beta | -6.18 |
| Outstanding Shares | 69,311,186 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -63.24 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -10.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.63 |
| Debt to Equity | -1.92 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$25.86 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.43%▲ 3.43% |
|---|---|
| Total Invested | $64.36M |
| Investors Holding | 17▲ 17.00% |
ESG Score
No data
About Alamar Biosciences, Inc.
222 employees
CEO: Yuling Luo Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated ...